Delivery Order SPE2DB22D9225-SPE2DB25FR8FJ
- Not listed
- On August 20, 2025, the Defense Logistics Agency awarded a delivery order valued at $10,461.10 to DMS Pharmaceutical Group Inc. for the supply of Cosentyx (secukinumab) 300 mg pen 2 mL injections. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The contract does not utilize a set-aside designation, and the pharmaceutical products will be...
- The Defense Logistics Agency awarded a delivery order valued at $13,735.58 to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300mg dose in 2-pen/mL formulation on August 25, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 26, 2025, represents a pharmaceutical supply requirement with performance taking place in Conshohocken, Pennsylvania. The award was made without set-aside designation to DMS Pharmaceutical Group, a woman-owned small business...
- The Defense Logistics Agency awarded a delivery order valued at $4,200.08 to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300 mg pen 2 ml on August 25, 2025, with completion expected by August 26, 2025. This firm fixed-price delivery order represents a specific pharmaceutical requisition issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, valued at $499.999 billion and extending through November 2026. The award carries no...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $3,382.36, is for the delivery of Cosentyx (secukinumab) 300 mg pens to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $13,456.01 by the Defense Logistics Agency (DLA) on August 13, 2025. The contract calls for the delivery of Cosentyx Unoready 300 mg pen 2ml pharmaceutical product to a location in Conshohocken, Pennsylvania, with an ultimate completion date of August 14, 2025. This delivery order was issued without a set-aside designation,...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on August 18, 2025, for Cosentyx Unoready 300 mg pen 2 ml pharmaceutical products. The contract is valued at $16,800.32 under a firm fixed-price arrangement with an ultimate completion date of August 19, 2025. This delivery order was issued without a set-aside designation, leveraging the contractor's...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $16,800.32 firm fixed-price contract is for the delivery of Cosentyx, a prescription medication, and has an ultimate completion date of April 30, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency...
- This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $16,911.80 contract is for the delivery of Cosentyx Unoready 300 mg pens to the Defense Logistics Agency (DLA), a defense agency. The contract has an ultimate completion date of October 23, 2024. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
- This federal contract award is for the delivery of Cosentyx (secukinumab) 300 mg pens to the Defense Logistics Agency (DLA), a defense agency within the U.S. Department of Defense (DoD). The contract, valued at $3,382.36, was awarded to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a firm fixed-price delivery order with no set-aside designation, running from the award date of July 30, 2024 through the ultimate...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $31,640.70 contract is for the supply of Cosentyx 300 mg pen injectors. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a wide range of pharmaceutical products to support the medical supply...
- SPE2DB22D9225Indefinite Delivery Contract
- SPE2DB22D9225-SPE2DB25FR8FJDelivery Order
The Defense Logistics Agency awarded a $16.8K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cosentyx (secukinumab) 300 mg pen injections. The order, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed-price delivery under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $500 million and valid through November 2026. No set-aside designation was applied to this particular delivery order, though the contractor maintains its competitive advantage as a woman-owned small business in federal procurement markets. This delivery order is issued under the SPE2DB program, which authorizes DLA to procure pharmaceutical products and medical supplies supporting Department of Defense healthcare facilities worldwide. Cosentyx is a biologic immunosuppressant medication used in the treatment of various autoimmune conditions, and its procurement through this contract ensures steady supply availability to military health facilities. DMS Pharmaceutical Group's extensive portfolio of federal pharmaceutical contracts demonstrates its established role as a critical supplier within the Defense supply chain, consistently delivering branded and generic prescription drugs, biologics, and medical consumables to support military healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $16.8k | 7/25/25 |